Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
A phase 2 trial of Dacarbazine in sarcomas, run by Philogen S.p.A., active and no longer recruiting.
Overview
Efficacy and Safety of L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma is a phase 2 interventional study registered as NCT04733183 by Philogen S.p.A., with 98 participants planned, started 2020-08-28 and due to reach its primary completion in 2025-12. Interventions recorded: Dacarbazine, onfekafusp alfa. Conditions listed: Soft Tissue Sarcoma. No results are recorded here; the registry entry is the source.
Setting
A Randomized Study to Investigate the Efficacy and Safety of the Tumor-targeting Human Antibody-cytokine Fusion Protein L19TNF in Previously Treated Patients with Advanced Stage or Metastatic Soft-tissue Sarcoma
Phase
Phase 2
Sponsor
Philogen S.p.A.
Registry
Enrolled
98